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1479 (Burton), which would have 
specified that, for purposes of the Robert 
W. Crown California Children's Services 
Act, any condition designated by the 
Director of Health Services as treatable by 
an ophthalmologist is deemed treatable by 
an optometrist if the condition is within 
the scope of practice of optometry. 
■ RECENT MEETINGS 
At its August 24 meeting, the Board 
reported on a discussion with the Medical 
Board of California's (MBC) Division of 
Allied Health Professions regarding exist-
ing law as it relates to the relationship 
between optometrists and opticians shar-
ing office space. Business and Professions 
Code section 655 prohibits optometrists 
and opticians from entering into any 
"membership, proprietary interest, co-
ownership, landlord-tenant relationship, 
or any profit-sharing arrangement in any 
form, directly or indirectly .... " The Board 
of Optometry interprets section 655 as 
prohibiting an optician from sharing of-
fice space with an optometrist. However, 
the Medical Board's Registered Dispens-
ing Optician Program (RDO) contends 
that, so long as there is no violation of 
section 655, an optician may share office 
space with an optometrist. 
RDO further contends that no con-
sumer harm can result from an optician 
sharing an office with an optometrist, and 
that it is to consumers' benefit to have an 
optometrist in the same office. According 
to Attorney General's Opinion No. 80-417 
(March 4, 1981 ), the legislature intended 
to prohibit landlord-tenant business 
relationships between optometrists and 
opticians "in order to eliminate the poten-
tial conflicts of interest inherent in them." 
All of the agencies involved are expected 
to further investigate the issues involved; 
MBC is considering whether to request a 
second legal opinion in light of repeated 
inquiries regarding the propriety of office-
sharing relationships. 
■ FUTURE MEETINGS 
To be announced. 
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Pursuant to Business and Professions Code section 4000 et seq., the Board 
of Pharmacy grants licenses and permits 
to pharmacists, pharmacies, drug 
manufacturers, wholesalers and sellers of 
hypodermic needles. It regulates all sales 
of dangerous drugs, controlled substances 
and poisons. The Board is authorized to 
adopt regulations, which are codified in 
Di vision 17, Title I 6 of the California 
Code of Regulations (CCR). To enforce its 
regulations, the Board employs full-time 
inspectors who investigate accusations 
and complaints received by the Board. 
Investigations may be conducted openly 
or covertly as the situation demands. 
The Board conducts fact-finding and 
disciplinary hearings and is authorized by 
law to suspend or revoke licenses or per-
mits for a variety of reasons, including 
professional misconduct and any acts sub-
stantially related to the practice of phar-
macy. 
The Board consists of ten members, 
three of whom are public. The remaining 
members are pharmacists, five of whom 
must be active practitioners. All are ap-
pointed for four-year terms. 
■ MAJOR PROJECTS 
"Operation Goldpill" Targets Phar-
macy Fraud. On June 30, U.S. Attorney 
General William Barr and FBI Director 
William Sessions announced that more 
than 1,000 FBI agents and 120 other 
federal law enforcement officers were 
making arrests, conducting searches, and 
seizing assets in over 50 cities nationwide, 
including San Francisco, as part of 
"Operation Goldpill," the most 
widespread criminal fraud investigation 
of the health care industry ever carried out 
by the FBI. At this writing, federal 
authorities have seized 56 pharmacies and 
arrested 82 pharmacists, including one 
San Francisco-based pharmacist. 
Operation Goldpill consisted of a two-
year FBI investigation which uncovered 
illegal diverting, repackaging, and dis-
tribution of medications and intentional 
excessive or false billing by pharmacists 
which defrauded federally-funded 
programs and private insurance com-
panies. Among other things, the FBI found 
evidence that numerous pharmacists were 
filling prescriptions with generic drugs 
and charging consumers for more expen-
sive brand name drugs, billing Medicaid 
and insurance carriers multiple times, and 
billing for prescriptions never written or 
filled. The federal government is charging 
such individuals with fraud and con-
spiracy offenses which carry prison terms 
of five to fifteen years and fines up to 
$250,000. 
OAL Approves Pharmacy Tech-
nician Regulations. On August 12, the 
Office of Administrative Law (OAL) ap-
proved the Board's amendment to section 
1717(c) and adoption of new sections 
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1793-1793. 7, Title 16 of the CCR. This 
regulatory action establishes qualifica-
tions and registration procedures for phar-
macy technicians who may assist 
registered pharmacists with specified 
tasks, pursuant to AB 1244 (Chapter 841, 
Statutes of 1991 ), and should pave the way 
for implementation of the Board's new 
oral consultation requirement (see infra). 
{12:2&3 CRLR 135] 
Patient Consultation Regulations. 
On May 28, OAL approved the Board's 
amendments to sections 1707 .1 and 
1707 .2, Title 16 of the CCR, delaying until 
November 1 the effective date of the 
Board's patient consultation regulations, 
which require pharmacists to maintain 
patient medication profiles for all ongoing 
patient-consumers and to provide an oral 
consultation to each patient or patient's 
agent whenever a new prescription is dis-
pensed, with specified exceptions. 
[12:2&3 CRLR 135] 
On August 28, the Board published 
notice of its intent to further amend sec-
tions 1707 .1 and 1707 .2, and to adopt 
section 1707 .3, regarding the patient con-
sultation requirements. According to the 
Board, these proposed changes would 
align existing California pharmacy 
regulations with provisions of the federal 
Omnibus Budget Reconciliation Act of 
1990 (OBRA 90) which establish patient 
consultation by pharmacies as a require-
ment for Medicaid-covered patients and 
specifies required and permissive duties 
for pharmacists in this regard. 
As of November 1, section 1707 .1 re-
quires a pharmacy to maintain a patient 
medication profile for each patient it ser-
ves and specifies certain elements this 
profile shall contain for each patient and 
each prescription. Section 1707.1 also 
specifies the retention period for the 
patient's medication profile. The Board's 
proposed amendments to section 1707.1 
would add several express identifiers re-
quired by OBRA 90, such as the patient's 
telephone number, date of birth or age, and 
gender. Also, section 1707.l(a)(l)(C) 
would be amended to require that the 
patient medication record include any of 
the following which may relate to drug 
therapy: patient allergies, idiosyncracies, 
all prior and current medications includ-
ing non-prescription medications and 
relevant devices, or medical conditions 
which are communicated by the patient or 
the patient's agent. 
As of November 1, section 1707.2 
clarifies the duty to consult and the notice 
to consumers regarding the consultation, 
which must be conspicuously posted in 
each pharmacy subject to Business and 
Professions Code section 4333. The 
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Board's proposed amendments to section 
1707.2 would do the following: 
-require, in situations where the 
patient or the patient's agent is not present 
to receive consultation from a pharmacist, 
that the patient or agent receives written 
notice of his/her right to request consult-
ation and a telephone number from which 
the patient may obtain oral consultation 
from a pharmacist who has ready access 
to the patient's record; 
-require an amplification of the 
precautions and relevant warnings that 
must be given during consultation (i.e., 
that the pharmacist must advise the patient 
of common severe side or adverse effects 
or interactions and therapeutic contrain-
dications that may be encountered); and 
-incorporate optional elements of a 
consultation which OBRA 90 mandates if 
warranted in the professional judgment of 
the pharmacist, such as the name and 
description of the medication, the route of 
administration, dosage form, dosage, and 
duration of drug therapy, any special 
directions for use and storage, precautions 
for preparation and administration by the 
patient, prescription refill information, ap-
propriate actions required if common 
severe side or adverse effects occur, and 
action to be taken in the event of a missed 
dose. 
The Board's proposed new section 
1707 .3 would make the current regula-
tions consistent with the prospective drug 
utilization review requirements of OBRA 
90, by requiring that a pharmacist perform 
a review of drug therapy and the patient 
medication record before each prescrip-
tion is filled or delivered to the patient or 
the patient's agent. This review must in-
clude screening for severe potential drug 
therapy problems. 
The Board was scheduled to hold a 
public hearing on these proposed 
regulatory actions on October 14 in Los 
Angeles. 
In a related matter, at its July 28 meet-
ing, the Board discussed its concern over 
the delivery of medications to patients 
through the mail, and how consumers 
receiving such medication would receive 
the mandated patient consultation. To ad-
dress these concerns, the Board has 
grafted proposed amendments to Business 
and Professions Code section 4050.2 and 
to section 1707.2, Title 16 of the CCR. The 
regulatory changes to section 1707 .2 
would provide that when a patient or agent 
is not present to receive the required oral 
consultation, including but not limited to 
a prescription that is shipped by mail, the 
pharmacist shall ensure that the patient 
receives written notice of his/her right to 
request consultation and a telephone num-
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ber by which the patient may obtain oral 
consultation from a pharmacist who has 
ready access to the patient's record. At this 
writing, the Board has not yet published 
notice regarding this regulatory revision 
in the California Regulatory Notice 
Register. 
The proposed legislative change to 
Business and Professions Code section 
4050.2 would require any pharmacy 
which ships or mails prescriptions to a 
patient in California to provide a toll-free 
service for a patient to contact a phar-
macist who has access to that patient's 
records; this telephone service would be 
required to be available during specific 
periods of the day and a minimum number 
of hours during the week. The Board may 
seek to have this change included in the 
Department of Consumer Affairs' om-
nibus bill during the 1993-94 legislative 
session. 
Board Exempts Kaiser From Patient 
Consultation Requirement. On June 26, 
Kaiser Permanente and the University of 
Southern California's School of Pharmacy 
submitted a joint proposal to the Board 
which would exempt Kaiser from im-
plementing the Board's patient consult-
ation requirement in all its facilities, and 
instead allow it to implement a research 
model. Kaiser's proposal outlined two 
complementary controlled trials designed 
to compare the effects of three different 
consultation and pharmacy practice 
models on patient health outcomes, 
medication compliance, and resource 
utilization. The three models Kaiser 
proposed to test are the "status quo" prior 
to November I (pharmacist consultation 
only when deemed necessary by a phar-
macist or upon a patient's request), man-
datory pharmacist consultation for new or 
changed prescriptions, and an alternative 
model which provides pharmaceutical 
care to patients at high risk for drug-re-
lated problems. Section 1731, Title I 6 of 
the CCR, authorizes the Board to waive 
any of its regulations as to an accredited 
school of pharmacy recognized by the 
Board if the dean of the school of phar-
macy submits-and the Board ap-
proves-an experimental plan or program 
regarding new and innovative methods for 
drug handling, teaching, research, or to 
develop new and better methods or con-
cepts involving the ethical practice of 
medicine. Any such plan or program ap-
proved by the Board shall have definite 
time limitations; progress reports must be 
filed as required by the Board. At its July 
28-29 meeting, the Board approved the 
USC/Kaiser proposal, thus granting 
Kaiser an exemption from the Board's 
new patient consultation regulations. 
OAL Disapproves Compounding for 
Office Use Regulations. On June 22, 
OAL disapproved the Board's proposal to 
adopt new section 1716.1 and I 716.2, 
Title 16 of the CCR. Section 1716. l would 
define the quantity of compounded 
medication which a pharmacist may fur-
nish to a prescriber for office use under 
Business and Professions Code section 
4046(c}(l), and section 1716.2 would 
specify the minimum types of records that 
pharmacies must keep when they furnish 
compounded medication to prescribers in 
quantities larger than required for the 
prescriber's immediate office use or when 
a pharmacy compounds medication for 
future furnishing. {12:2&3 CRLR 136] 
OAL disapproved the proposed sec-
tions on the basis that they failed to meet 
the clarity and necessity standards of the 
Administrative Procedure Act (APA); 
OAL also found that the Board failed to 
respond adequately to comments, as is 
required by the APA. Specifically, OAL 
determined that the regulations use un-
defined, ambiguous, and confusing terms; 
fail to specify the standards which will 
apply; and differ from the Board's stated 
explanation of intent. Also, OAL found 
that the Board did not provide the factual 
basis for limiting supplies of compounded 
medications to 180 days, in packaging for 
72 hours or less, or for limiting prescribers 
to furnishing no more than 72-hour sup-
plies to their patients. 
The Board has 120 days from the date 
ofOAL's disapproval to amend and resub-
mit the rulemaking file to OAL for review. 
Pharmacist-in-Charge Regulations. 
On May 27, the Board held a public hear-
ing on its proposal to amend section 
1709 .1, Title 16 of the CCR, which would 
allow a pharmacist to be the pharmacist-
in-charge at two pharmacies if only one of 
these pharmacies is open at any given time 
and if that pharmacist is the only phar-
macist at each pharmacy. The Board 
received no written or oral comments 
regarding this proposed amendment, and 
unanimously adopted it. This proposal 
awaits review and approval by OAL. 
{ 12:2&3 CRLR 136] 
Other Regulatory Action. The fol-
lowing is an update on other regulatory 
changes recently pursued by the Board 
[ 12:2&3 CRLR 136]: 
• Licensure of Drug Wholesalers. On 
June 22, OAL approved the Board's 
regulatory amendments to section 1780, 
Title 16 of the CCR, which change 
California's requirements for drug 
wholesalers so that they meet or exceed 
the standards of the federal government 
under the Prescription Drug Marketing 
Act of 1987. 
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• Medical Device Retailers Locked 
Storage. The rule making file regarding 
the Board's proposed adoption of new sec-
tions I 748.1 and I 748.2, Title 16 of the 
CCR, regarding the proper storage of 
dangerous devices at medical device 
retailer (MDR) retail sites, and the 
delivery of devices by MDRs to patients 
after hours or in emergency situations, 
awaits review and approval by OAL. 
• Partial Filling of Schedule II 
Prescriptions. On September 3, OAL ap-
proved the Board's adoption of new sec-
tion 1745, Title I 6 of the CCR, which 
permits the partial filling of Schedule II 
controlled substance prescriptions for in-
patients of skilled nursing facilities or for 
terminally ill patients. 
■ LEGISLATION 
The following is a status update on 
bills reported in detail in CRLR Vol. 12, 
Nos. 2 & 3 (Spring/Summer 1992) at 
pages 136-37: 
SB 2044 (Boatwright) declares legis-
lative findings regarding unlicensed ac-
tivity and authorizes all Department of 
Consumer Affairs boards, bureaus, and 
commissions, including the Board of 
Pharmacy, to establish by regulation a sys-
tem for the issuance of an administrative 
citation to an unlicensed person who is 
acting in the capacity of a licensee or 
registrant under the jurisdiction of that 
board, bureau, or commission. This bill 
was signed by the Governor on September 
28 (Chapter 1135, Statutes of I 992). 
AB 3415 (Tucker) excludes from the 
definition of "dangerous devices" any 
prosthetic or orthopedic devices that do 
not require a prescription. This bill also 
deletes an existing provision of Jaw which 
requires that any retailer who sells pros-
thetic or orthotic dangerous devices on the 
premises have a prescribed fitting room 
under certain circumstances. This bill was 
signed by the Governor on July 6 (Chapter 
121, Statutes of 1992). 
AB 3286 (Tucker) permits a medical 
device retailer to dispense, furnish, trans-
fer, or sell a dangerous device to a licensed 
physical therapist. This bill was signed by 
the Governor on July 18 (Chapter 271, 
Statutes of 1992). 
AB 2638 (Boland) would have 
provided that a medical device retailer 
may dispense, furnish, transfer, or sell a 
dangerous device to a licensed chiroprac-
tor. This bill was vetoed by the Governor 
on September 26. 
AB 2525 (Brown) and SB 1418 
(Moore) each would have established the 
Clean Needle and Syringe Exchange Pilot 
Project, and would have authorized phar-
macists, physicians, and certain persons 
authorized under the pilot project to fur-
nish hypodermic needles and syringes 
without a prescription or permit as 
prescribed through the pilot project. These 
bills were vetoed by the Governor on Sep-
tember 30. 
AJR 63 (Bronzan) urges the President 
and Congress to authorize the FDA to 
investigate a new transitional non-
prescription drug category available only 
through licensed pharmacists, with the 
goal of decreasing the time needed for the 
FDA to approve a drug for over-the-
counter status. This resolution was chap-
tered on July 23 (Chapter 83, Resolutions 
of 1992). 
AB 3133 (Hunter), among other 
things, specifies that no provision of law 
prohibits the sale of dangerous devices to 
licensed home health agencies and 
licensed hospices, as defined. This bill 
was signed by the Governor on September 
28 (Chapter 1104, Statutes of I 992). 
AB 2743 (Frazee) amends Business 
and Professions Code section 4038 to 
delete the exemption of pharmacies and 
licensed manufacturers from the defini-
tion of the term wholesaler, and deletes 
specific provisions providing for payment 
of costs of investigations and disciplinary 
proceedings with respect to pharmacists. 
This bill was signed by the Governor on 
September 30 (Chapter 1289, Statutes of 
1992). 
SB 664 (Calderon). Existing Jaw 
prohibits pharmacists, among others, from 
charging, billing, or otherwise soliciting 
payment from any patient, client, cus-
tomer, or third-party payor for any clinical 
laboratory test or service if the test or 
service was not actually rendered by that 
person or under his/her direct supervision, 
unless the patient is apprised at the first 
solicitation for payment of the name, ad-
dress, and charges of the clinical 
laboratory performing the service. This 
bill also makes this prohibition applicable 
to any subsequent charge, bill, or solicita-
tion. This bill was signed by the Governor 
on June 4 (Chapter 85, Statutes of 1992). 
AB 1226 (Hunter) repeals Business 
and Professions Code section 4047.7, 
which requires the Director of the Depart-
ment of Health Services to establish a 
formulary of generic drug types and drug 
products which the Director determines 
demonstrate clinically significant biologi-
cal or therapeutic inequivalence and 
which, if substituted, would pose a threat 
to the health and safety of patients receiv-
ing medication if that medication is sub-
stituted by a pharmacist in lieu of a brand 
name drug prescribed by a prescriber. This 
bill was signed by the Governor on August 
16 (Chapter 485, Statutes of 1992). 
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AB 855 (Hunter) requires that a 
general acute care hospital and acute 
psychiatric hospital establish and imple-
ment a written policy to ensure that each 
of its patients receives prescribed informa-
tion from a pharmacist or registered nurse 
unless already provided by a physician 
regarding medications received at the time 
of discharge. This bill was signed by the 
Governor on September 26 (Chapter 985, 
Statutes of 1992). 
SB 917 (Kopp) would have required 
certain health care service plans that 
propose to offer a pharmacy benefit or 
change their relationship with pharmacy 
providers to give written or published 
notice to pharmacy service providers of 
the plan's proposal, and give those 
providers an opportunity to submit a bid 
to participate in the plan's panel of 
providers on the terms proposed. This bill 
was vetoed by the Governor on July 29. 
AB 819 (Speier) was substantially 
amended and is no longer relevant to the 
Board. 
The following bills died in committee: 
SB 1986 (Marks), which would have 
prohibited disability insurers that provide 
coverage for pharmaceutical services 
from requiring their insureds or persons 
covered by the policy to obtain phar-
maceutical services exclusively from non-
resident pharmacies, and would have 
provided that insurers may not impose any 
limitat10ns on coverage of pharmaceutical 
services provided by in-state pharmacies 
that are not also imposed on nonresident 
pharmacies; and AB 2070 (Isenberg), 
which would have generally made it un-
lawful for specified healing arts licensees 
to refer a person to any laboratory, phar-
macy, clinic, or health care facility solely 
because the licensee has an ownership in-
terest in the facility. 
■ LITIGATION 
On June 24, the California Supreme 
court denied review of the Second District 
Court of Appeal's opinion in People v. 
Doss, No. B046265 (Apr. 1, 1992), in 
which the appellate court ruled that Busi-
ness and Professions Code section 4230 
does not confer blanket immunity on a 
pharmacist to possess controlled substan-
ces for any purpose on pharmacy 
premises. [12:2&3 CRLR 137] 
■ RECENT MEETINGS 
At its May 27-28 meeting, the Board 
elected Stephen E. Dibble and Gilbert 
Castillo to be Board president and vice-
president, respectively. These officers will 
each serve one-year terms. 
Also at its May 28-29 meeting, the 
Board agreed to pursue a budget change 
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proposal (BCP) for the 1993-94 fiscal 
year to redesign and augment the Board's 
enforcement unit. Specifically, the 
Board's BCP would request $333,000 in 
order to add three pharmacy inspectors 
and one consumer services representative, 
and to make permanent a limited-term of-
fice technician position established on 
July I. 
■ FUTURE MEETINGS 
January 20-21 in Sacramento. 
April 28-29 in Sacramento. 
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The Board of Registration for Profes-sional Engineers and Land Surveyors 
(PELS) regulates the practice of engineer-
ing and land surveying through its ad-
ministration of the Professional Engineers 
Act, sections 6700 through 6799 of the 
Business and Professions Code, and the 
Professional Land Surveyors' Act, sec-
tions 8700 through 8805 of the Business 
and Professions Code. The Board's 
regulations are found in Division 5, Title 
16 of the California Code of Regulations 
(CCR). 
The basic functions of the Board are to 
conduct examinations, issue certificates, 
registrations, and/or licenses, and ap-
propriately channel complaints against 
registrantsnicensees. The Board is addi-
tionally empowered to suspend or revoke 
registrations/licenses. The Board con-
siders the proposed decisions of ad-
ministrative law judges who hear appeals 
of applicants who are denied a registra-
tion/license, and those who have had their 
registration/license suspended or revoked 
for violations. 
The Board consists of thirteen mem-
bers: seven public members, one licensed 
land surveyor, four registered Practice Act 
engineers and one Title Act engineer. 
Eleven of the members are appointed by 
the Governor for four-year terms which 
expire on a staggered basis. One public 
member is appointed by the Speakerofthe 
Assembly and one by the Senate Rules 
Committee. 
118 
The Board has established four stand-
ing committees and appoints other special 
committees as needed. The four standing 
committees are Administration, Enforce-
ment, Examination/Qualifications, and 
Legislation. The committees function in 
an advisory capacity unless specifically 
authorized to make binding decisions by 
the Board. 
Professional engineers are registered 
through the three Practice Act categories 
of civil, electrical, and mechanical en-
gineering under section 6730 of the Busi-
ness and Professions Code. The Title Act 
categories of agricultural, chemical, con-
trol system, corrosion, fire protection, in-
dustrial, manufacturing, metallurgical, 
nuclear, petroleum, quality, safety, and 
traffic engineering are registered under 
section 6732 of the Business and Profes-
sions Code. 
Structural engineering and geotechni-
cal engineering are authorities linked to 
the civil Practice Act and require an addi-
tional examination after qualification as a 
civil engineer. 
■ MAJOR PROJECTS 
PELS Searches for New Executive 
Officer. In late August, PELS Executive 
Officer Darlene Stroup announced her 
decision to step down as EO but to con-
tinue working for the Board on a "special 
assignment" until October 31. Following 
that announcement, PELS President Larry 
Dolson appointed Curt Augustine to serve 
as PELS' Interim EO until the Board can 
find a permanent replacement for Stroup. 
At PELS' September 25 meeting, Dolson 
departed from the meeting agenda and 
failed to introduce Augustine until well 
into the meeting; furthermore, Dolson did 
not discuss the details of Stroup's "special 
assignment" nor how the Board intends to 
pay for the services of two executive of-
ficers until Stroup's resignation becomes 
effective. 
At its September 25 meeting, the 
Board devoted substantial time to discuss-
ing the preferred qualifications for its new 
executive officer. Many Board members 
expressed interest in hiring a registered 
engineer; others focused on the need to 
hire an individual with substantial ad-
ministrative experience. The Board 
decided to solicit applicants who 
demonstrate ability in either area. 
Board Awards Professional Land 
Surveyor Consultant Contract. At 
PELS' June 5 meeting, Board members 
continued to debate whether PELS should 
use the bidding procedures specified in the 
"Little Brooks Act," Government Code 
section 4525 et seq., in soliciting ap-
plicants for its professional land surveyor 
consultant position. The Little Brooks Act 
provides a procedure for selecting private 
architectural, landscape architectural, en-
gineering, environmental, land surveying, 
and construction project management ser-
vices for public projects on the basis of 
demonstrated competence and profes-
sional qualifications necessary for satis-
factory performance of the job, as opposed 
to selection on the basis of minimum com-
petence and competitive bidding. Al-
though the Act does not indicate those 
situations when its bidding procedures 
must be used, Government Code section 
4529 does provide that the Act "shall not 
apply where the state or local agency head 
determines that the services needed are 
more of a technical nature and involve 
little professional judgment and that re-
quiring bids would be in the public inter-
est." The alternative procedure for award-
ing contracts involves the release of a re-
quest for proposals (RFP). Under the RFP 
process, bids are evaluated to determine if 
they meet the minimum qualifications; 
thereafter, the contract is awarded to the 
lowest bidder who possesses the mini-
mum qualifications. 
PELS determined that its land sur-
veyor consultant would-among other 
things-review complaints to determine 
whether a violation of the Professional 
Land Surveyors' Act has occurred; serve 
as a witness for the Board in disciplinary 
hearings against land surveyors; respond 
to requests for information and interpreta-
tion of the Act; review and coordinate land 
surveyor examination appeals; act as in-
house consultant for the Board staff rela-
tive to land surveying questions; and 
develop and monitor regulatory packages 
relating to land surveying. The job 
description prepared by the Board estab-
lished as 50% of the evaluation criteria 
"land surveying experience and 
knowledge of professional methods, pro-
cedures, requirements, and standards." 
However, Department of Consumer Af-
fairs (DCA) legal counsel Don Chang ad-
vised the Board that the services called for 
in the job description would be of a tech-
nical nature rather than the professional 
practice of land surveying, and that com-
pliance with the RFP procedure, as op-
posed to the Little Brooks Act, was ap-
propriate. Thus, PELS issued an RFP; 
however, the Board received only two 
proposals, only one of which scored above 
the minimum qualifying score. At its 
December 1991 meeting, PELS decided to 
reject the bids received pursuant to the 
RFP process and directed staff to rewrite 
the proposal to include consideration of ' 
the Little Brooks Act criteria. The Board 
took this action despite that fact that it has 
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